"Alendronate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
| Descriptor ID |
D019386
|
| MeSH Number(s) |
D02.705.429.500.100
|
| Concept/Terms |
Alendronate- Alendronate
- Aminohydroxybutane Bisphosphonate
- Bisphosphonate, Aminohydroxybutane
- 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate
- 4 Amino 1 Hydroxybutylidene 1,1 Biphosphonate
Alendronate Sodium- Alendronate Sodium
- Sodium, Alendronate
- Alendronate Monosodium Salt, Trihydrate
|
Below are MeSH descriptors whose meaning is more general than "Alendronate".
Below are MeSH descriptors whose meaning is more specific than "Alendronate".
This graph shows the total number of publications written about "Alendronate" by people in this website by year, and whether "Alendronate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alendronate" by people in Profiles.
-
Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia. Med Clin (Barc). 2018 07 23; 151(2):65-67.
-
Natural history and risk factors for adjacent vertebral fractures in the fracture intervention trial. Spine (Phila Pa 1976). 2013 Dec 01; 38(25):2201-7.
-
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion. J Oral Maxillofac Surg. 2012 Feb; 70(2):325-30.
-
"Pill esophagitis"--the case of alendronate. N Engl J Med. 1996 Oct 03; 335(14):1058-9.